Gunnar Casserstedt
Président chez KD Incentive AB
Provenance du réseau au premier degré de Gunnar Casserstedt
Entité | Type d'entité | Industrie | |
---|---|---|---|
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
11
| Operating Division | Investment Managers | 11 |
KD Incentive AB
3
| Subsidiary | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Gunnar Casserstedt via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Dako Denmark ApS
Dako Denmark ApS Medical SpecialtiesHealth Technology Dako Denmark A/S designs and manufactures cancer diagnostic systems. It produces reagents, antibodies, instruments, and software solutions to make diagnoses and determine treatments for patients suffering from cancer. The firm's product areas encompass Immunohistochemistry, pharmacoDiagnostics, molecular pathology, Hematoxylin and Eosin stain, special stains, flow Cytometry, and specific proteins. The company was founded by Niels Harboe in 1966 and is headquartered in Glostrup, Denmark. | Medical Specialties | Director/Board Member | |
OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
Accuro Immunology AB
Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
University of Lund | College/University | Corporate Officer/Principal Graduate Degree | |
KDev Exploratory AB
KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Chairman | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
PROMIMIC AB | Medical Specialties | Director/Board Member Director/Board Member | |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Founder | |
Eribis Pharmaceuticals AB
Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Pharmaceuticals: Major | Director/Board Member | |
Umecrine AB
Umecrine AB BiotechnologyHealth Technology Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden. | Biotechnology | Director/Board Member Chairman | |
LIPIDOR AB | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
KCIF Fund Management AB | Director/Board Member Chief Executive Officer Chief Executive Officer Chairman Director/Board Member | ||
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
ASARINA PHARMA AB | Pharmaceuticals: Major | Director/Board Member Public Communications Contact | |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Corporate Officer/Principal | |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Chairman | |
NEOS AB | Medical Specialties | Chairman Director/Board Member | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal Chief Executive Officer Chairman Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Investment Officer Corporate Officer/Principal Corporate Officer/Principal General Counsel Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
Palette Life Sciences AB
Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
SYNACT PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
NEXTCELL PHARMA AB | Pharmaceuticals: Major | Founder | |
Arctic Asset Management AS (Sweden)
Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Investment Managers | Founder Analyst-Equity | |
QureTech Bio AB | Director/Board Member |
Statistiques
Internationale
Suède | 45 |
Danemark | 4 |
Etats-Unis | 2 |
Finlande | 2 |
Norvège | 2 |
Sectorielle
Health Technology | 39 |
Commercial Services | 8 |
Finance | 3 |
Consumer Services | 2 |
Opérationnelle
Director/Board Member | 132 |
Corporate Officer/Principal | 38 |
Chairman | 38 |
Independent Dir/Board Member | 19 |
Chief Executive Officer | 15 |
Relations les plus connectées
Insiders | |
---|---|
Bo Jesper Hansen | 34 |
Stig Lennart Hansson | 32 |
Sten Gunnar Otto Skolling | 32 |
Torbjørn Bjerke | 27 |
Terje Kalland | 20 |
Carl Harald Janson | 19 |
Ola Flink | 19 |
Hans-Peter Torsten Ekre | 16 |
Ulf Göran Richenberg | 10 |
Johan Dighed | 10 |
Robin Wright | 8 |
Conny Börje Bogentoft | 7 |
Daniel Bolanowski | 5 |
Elisabet Gimbringer | 3 |
- Bourse
- Insiders
- Gunnar Casserstedt
- Connexions Sociétés